APA (7th ed.) Citation

M, C., A, S., T, P., CJ, T., VM, S., KB, N., . . . N, P. (2025). Acasunlimab, an Fc-inert PD-L1×4-1BB bispecific antibody, combined with PD-1 blockade potentiates antitumor immunity via complementary immune modulatory effects. Journal for immunotherapy of cancer, 13(4), . https://doi.org/10.1136/jitc-2024-011377

Chicago Style (17th ed.) Citation

M, Capello, et al. "Acasunlimab, an Fc-inert PD-L1×4-1BB Bispecific Antibody, Combined with PD-1 Blockade Potentiates Antitumor Immunity via Complementary Immune Modulatory Effects." Journal for Immunotherapy of Cancer 13, no. 4 (2025). https://doi.org/10.1136/jitc-2024-011377.

MLA (9th ed.) Citation

M, Capello, et al. "Acasunlimab, an Fc-inert PD-L1×4-1BB Bispecific Antibody, Combined with PD-1 Blockade Potentiates Antitumor Immunity via Complementary Immune Modulatory Effects." Journal for Immunotherapy of Cancer, vol. 13, no. 4, 2025, https://doi.org/10.1136/jitc-2024-011377.